HeartBeam Partners with HeartNexus to Provide 24/7 Cardiology Reader Services
TL;DR
HeartBeam's partnership with HeartNexus provides a competitive edge by offering 24/7 cardiology services that enable faster cardiac assessment outside medical facilities.
HeartBeam's patented 3D technology captures 30-second cable-free ECG recordings that transmit data to HeartNexus cardiologists for immediate interpretation and analysis.
This collaboration makes medical-grade cardiac monitoring accessible beyond hospital walls, improving cardiac care accessibility and potentially saving lives through timely interventions.
HeartBeam's FDA-cleared 3D ECG technology can record heart signals from three directions and synthesize them into a 12-lead ECG using portable devices.
Found this article helpful?
Share it with your network and spread the knowledge!
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through personalized insights, announced a partnership with HeartNexus Inc., a network of board-certified cardiologists specializing in cardiac test interpretation, peer consultations, and telemedicine visits. The collaboration enables HeartBeam to offer 24/7 cardiology reader services for patients experiencing cardiac symptoms outside traditional care settings. Using HeartBeam's patented 3D technology, patients can capture a 30-second, cable-free ECG recording anytime symptoms occur, transmitting the data to HeartNexus cardiologists for immediate interpretation.
Robert Eno, CEO of HeartBeam, stated that working with HeartNexus accelerates the company's mission to make medical-grade cardiac monitoring accessible beyond the walls of a medical facility. The partnership expands HeartBeam's ecosystem with real-time cardiology feedback and future integration of AI wellness and wearable features. HeartBeam is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence.
Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024. The 12-Lead ECG synthesis software is under FDA review. The Company holds over 20 issued patents related to technology enablement. Additional information about the company is available in their newsroom at https://ibn.fm/BEAT. Full terms of use and disclaimers applicable to all content are available on the InvestorBrandNetwork website.
Curated from NewMediaWire
